Lineage Cell Therapeutics (LCTX) Cash & Current Investments (2010 - 2026)

Lineage Cell Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $62.7 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 30.92% year-over-year to $62.7 million in Q1 2026; TTM through Mar 2026 was $62.7 million, a 30.92% increase from a year earlier, with the FY2025 full-year figure at $61.0 million, up 41.64% from the prior year.
• Cash & Current Investments rose to $62.7 million in Q1 2026 per LCTX's latest filing, from $61.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $79.9 million in Q1 2022 and bottomed at $30.0 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $45.9 million (2023), against an average of $49.7 million.
• Across the five-year window, Cash & Current Investments sank 48.19% in 2023 and surged 43.52% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $57.9 million in 2022, then sank by 48.19% to $30.0 million in 2023, then surged by 43.52% to $43.0 million in 2024, then soared by 41.64% to $61.0 million in 2025, then climbed by 2.89% to $62.7 million in 2026.
• Per Business Quant, the three latest LCTX Cash & Current Investments figures stand at $62.7 million (Q1 2026), $61.0 million (Q4 2025), and $32.2 million (Q3 2025).